Nykode Therapeutics AS
NYKD
Rank in Stocks
#18739
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers... Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Share Price
$0.31640848
Last synced: 2026-11-09
Market Cap
$123.89M
Change (1 day)
0.12%
Change (1 year)
42.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nykode Therapeutics AS (NYKD)
Category
Healthcare
Operating Margin for Nykode Therapeutics AS (NYKD)
Operating Margin as of November 2026 TTM: -26,438.77%
According to Nykode Therapeutics AS's latest financial reports, its current operating margin (TTM) is -26,438.77%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Nykode Therapeutics AS from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -26,438.77% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -556.87% | 23.70% |
| 2023 | -450.18% | -39.29% |
| 2022 | -741.57% | 2,237.13% |
| 2021 | -31.73% | -138.27% |
| 2020 | 82.91% | -108.40% |
| 2019 | -987.46% | 80.61% |
| 2018 | -546.73% | 57.15% |
| 2017 | -347.91% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nykode Therapeutics AS's operating margin
What is Nykode Therapeutics AS's operating margin?
Nykode Therapeutics AS's operating margin is -26,438.77%, as of Nov 2026.
What was Nykode Therapeutics AS's operating margin in 2025?
In 2025, Nykode Therapeutics AS's operating margin was 0.00%, compared with -556.87% in 2024.
How has Nykode Therapeutics AS's operating margin changed since 2020?
From 2020 to 2025, Nykode Therapeutics AS's operating margin was highest in 2020 (82.91%) and lowest in 2022 (-741.57%).
How does Nykode Therapeutics AS's operating margin compare with similar companies?
Nykode Therapeutics AS's operating margin (-26,438.77%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.